By Isaac Taylor
Astellas Pharma Inc. and Seagen Inc. announced Wednesday that the European Commission has approved a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
The approval is for patients who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor.
Urothelial cancer is the most common type of bladder cancer, comprising 90% of cases. Globally, roughly 573,000 new cases of bladder cancer and 212,000 deaths are reported annually.
The EC approval is supported by data from a global phase three trial that showed an overall survival benefit compared with chemotherapy.
Write to Isaac Taylor at isaac.taylor@wsj.com
(END) Dow Jones Newswires
04-13-22 1216ET